Brainstorm Cell Therapeutics Stock Investor Sentiment
| BCLI Stock | USD 1.71 0.03 1.72% |
Under 62% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
Brainstorm |
Brainstorm Cell Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Brainstorm Cell that are available to investors today. That information is available publicly through Brainstorm media outlets and privately through word of mouth or via Brainstorm internal channels. However, regardless of the origin, that massive amount of Brainstorm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Brainstorm Cell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Brainstorm Cell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Brainstorm Cell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Brainstorm Cell alpha.
Brainstorm Cell Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3 | 09/16/2024 |
2 | BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting | 09/24/2024 |
3 | Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3 | 09/30/2024 |
4 | Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3 | 10/01/2024 |
5 | BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn Trial at the 2024 Maxim Healthcare Virtual Summit | 10/07/2024 |
6 | Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3 | 10/10/2024 |
7 | Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3 | 10/11/2024 |
8 | BrainStorm Cell Therapeutics regains compliance with Nasdaq | 10/30/2024 |
9 | Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3 | 11/12/2024 |
10 | BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Canada Finance | 11/14/2024 |
11 | BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis on December 11, 2024 | 12/02/2024 |
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |